NZ Shrooms for Depression: Legal Update
new Zealand just approved psilocybin for treatment-resistant depression,joining a global shift toward psychedelic medicine. Associate Health Minister David Seymour announced teh change, allowing approved psychiatrists to prescribe “magic mushrooms” for patients. This marks a significant development, with Dr. Cameron Lacey becoming the first approved psychiatrist. The role of psilocybin and its medicinal use is under scrutiny worldwide. Other countries, like Australia, Switzerland and Canada, also are exploring this novel approach.The U.S. view, though, is still very different. With its growing popularity,learn how New Zealand is at the forefront of these developments,and witness the therapeutic purposes of these compounds flourish to its full role,as showcased in News Directory 3 coverage. Discover what’s next in this evolving treatment landscape.
New Zealand Approves Psilocybin for Treatment-Resistant Depression
Updated June 18, 2025
New Zealand has joined a growing list of countries permitting the medicinal use of psilocybin, the psychoactive compound found in so-called “magic mushrooms.” Associate Health Minister David Seymour announced Wednesday that approved psychiatrists can now prescribe psilocybin for patients battling treatment-resistant depression. The U.S. still classifies psilocybin as having “no currently accepted medical use” and a high potential for abuse.
Seymour called the policy a “real breakthrough,” noting that Dr. Cameron Lacey, a University of Otago professor, is the first psychiatrist approved. Lacey, who has prior experience prescribing psilocybin in clinical trials, will face strict reporting and record-keeping mandates. While Seymour hopes more psychiatrists will seek clearance, he emphasized that the drug remains an “unapproved medicine.”
The psilocybin proclamation coincided with relaxed rules for melatonin, a common sleep aid. While Seymour pledged expanded access to both treatments, a specific timeline remains unclear. The role of psilocybin in mental health treatment is under review globally, with New Zealand’s decision highlighting the potential medicinal use of controlled substances and the therapeutic purposes they may serve.
Other countries have also moved toward allowing medicinal psilocybin.Australia authorized prescriptions for specific mental health conditions in 2023. Switzerland has permitted the use of LSD, MDMA, and psilocybin for research and treatment since 2014.canada allows regulated medical use under strict conditions.
In the U.S., Oregon legalized therapeutic psilocybin in 2020, though access remains limited to licensed service centers, with sessions costing up to $2,000, according to the AP. Colorado legalized regulated medical use in 2022, issuing the first licenses this year. New Mexico followed suit in April, legalizing use in approved settings for specific conditions. Minnesota and Massachusetts are also considering similar legislation.
What’s next
As more regions explore the potential of psilocybin, the focus shifts to research, regulation, and ensuring safe and effective treatment protocols for patients with mental health conditions.